Hodgkin's lymphoma Posts Page 2 on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Evaluating intensive first-line treatment for patients with advanced Hodgkin’s lymphoma

Posted by on Nov 27, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with advanced Hodgkin’s lymphoma (HL) who received intensive first-line treatment. This study concluded that intensive first-line treatment with or without radiotherapy led to better long-term outcomes in these patients. Some background For patients with advanced HL,...

Read More

Evaluating survival outcomes after brentuximab vedotin treatment for relapsed or refractory Hodgkin’s lymphoma

Posted by on Nov 22, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the impact of brentuximab vedotin (Adcetris) on the survival of patients with relapsed or refractory (does not respond to treatment) classical Hodgkin’s lymphoma (cHL). This study concluded that brentuximab vedotin significantly improved survival in these patients. Some background Patients with cHL who...

Read More

Outcomes of reduced-intensity conditioning before alloSCT for relapsed or refractory Hodgkin lymphoma

Posted by on Nov 18, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of reduced-intensity conditioning followed by allogeneic stem cell transplantation (alloSCT) in patients with Hodgkin’s lymphoma (HL). This study concluded that this treatment improved survival outcomes in these patients. Some background AlloSCT is an effective therapy for patients with HL who...

Read More

A review of the side-effects of Nivolumab (Opdivo) treatment for Hodgkin Lymphoma.

Posted by on Nov 16, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This paper summarised the side effects associated with the use of nivolumab (Opdivo) for the treatment of Hodgkin Lymphoma. The main finding was that patients treated with nivolumab may experience immune-related side effects. Some background Brentuximab vedotin (Adcetris) and stem cell transplant are often used to treat classical...

Read More

Evaluating brentuximab vedotin after alloSCT in patients with recurrent Hodgkin Lymphoma

Posted by on Nov 8, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of brentuximab vedotin (Adcetris) treatment for patients with relapsed (recurrent) or progressive (tumor grows or spreads) Hodgkin’s lymphoma (HL) after allogeneic (allo) stem cell transplantation (SCT). This study concluded that brentuximab vedotin is safe and effective for these patients. Some...

Read More

Evaluating the long-term outcomes of brentuximab vedotin after stem cell transplantation for classical Hodgkin’s lymphoma

Posted by on Oct 29, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term survival and safety of brentuximab vedotin (Adcetris) treatment for patients with classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation (auto-SCT; patient's own healthy stem cells are retrieved and then returned into the body after cancer has been removed with chemotherapy...

Read More

Evaluating lenalidomide plus everolimus for relapsed or refractory lymphoma

Posted by on Oct 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of lenalidomide (Revlimid) plus everolimus (Afinitor) in pretreated patients with relapsed (recurrent) or refractory (does not respond to treatment) lymphoma. This study concluded that this combination was well-tolerated and showed promising effectiveness in these patients. Some...

Read More

Evaluating short-course ABVD chemotherapy in patients with early-stage Hodgkin lymphoma

Posted by on Sep 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of short-course (2 cycles) ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy with interim PET scanning in previously untreated patients with early-stage (stage 1 – 2) Hodgkin’s lymphoma (HL). This study concluded that short-course ABVD was effective in the majority of...

Read More

Evaluating BendaEAM chemotherapy before stem cell transplantation for relapsed lymphoma

Posted by on Sep 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the BendaEAM (bendamustine, etoposide, cytarabine, melphalan) in patients with lymphoma undergoing autologous stem cell transplantation (auto-SCT). This study concluded that BendaEAM is a feasible option for these patients, with minimal side effects. Some background High-dose...

Read More